Farther Finance Advisors LLC Acquires 77 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Farther Finance Advisors LLC lifted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 20.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 456 shares of the biotechnology company’s stock after purchasing an additional 77 shares during the period. Farther Finance Advisors LLC’s holdings in United Therapeutics were worth $140,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Dunhill Financial LLC increased its stake in United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares during the period. State of Wyoming acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $62,000. Curat Global LLC bought a new stake in shares of United Therapeutics during the first quarter valued at approximately $63,000. Millstone Evans Group LLC acquired a new position in shares of United Therapeutics in the fourth quarter valued at $67,000. Finally, Natixis acquired a new position in shares of United Therapeutics in the fourth quarter valued at $85,000. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

UTHR has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Cantor Fitzgerald initiated coverage on shares of United Therapeutics in a report on Monday, June 2nd. They issued an “overweight” rating and a $405.00 target price on the stock. Bank of America cut their price target on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a report on Wednesday, June 11th. Wells Fargo & Company restated an “equal weight” rating and issued a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Finally, Morgan Stanley upped their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $393.08.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the transaction, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at $10,297,208.76. The trade was a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Raymond Dwek sold 4,000 shares of the business’s stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the transaction, the director now owns 1,750 shares in the company, valued at approximately $497,962.50. This trade represents a 69.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 79,500 shares of company stock valued at $23,907,950 over the last 90 days. Company insiders own 10.30% of the company’s stock.

United Therapeutics Trading Down 0.3%

UTHR stock opened at $290.75 on Friday. The stock has a market capitalization of $13.12 billion, a P/E ratio of 11.60, a price-to-earnings-growth ratio of 6.39 and a beta of 0.57. The firm has a 50-day moving average price of $300.99 and a 200-day moving average price of $327.99. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.17 EPS. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.